Multimodal Magnetic Resonance Imaging and ¹⁸F-L-Dihydroxyphenylalanine Positron Emission Tomography in Early Characterization of Pseudoresponse and Nonenhancing Tumor Progression in a Pediatric Patient With Malignant Transformation of Ganglioglioma Treated With Bevacizumab

Value of 18F-3,4-Dihydroxyphenylalanine PET/MR Image Fusion in Pediatric Supratentorial Infiltrative Astrocytomas: A Prospective Pilot Study

“…Prior research demonstrates that 18 F-FDG and 11 C-MET improve the quality of therapeutic management of pediatric brain tumors at the diagnostic, surgical, and postoperative level, particularly in ill-defined infiltrative tumors. 18 F-FDG presents some limitations in defining targets for biopsy in low-grade pediatric tumors, whereas 11 C-MET appears also to be a better tracer than 18 F-FDG for delineating tumor boundaries and for residual tumor detection (25,26). Other studies found a correlation between 18 F-FDG uptake and tumor malignancy; however, there was significant overlap between different grades of malignancy (27,28).…”

“…When compared with 18 F-FDG, presently the most widely available PET tracer, amino-acid analogs have shown higher sensitivity to gliomas because of the higher tumor-to-normal-tissue background ratios (9). Among amino-acid PET tracers, 18 F-3,4-dihydroxyphenylalanine ( 18 F-DOPA) is largely unexplored in pediatric brain tumors, with only 3 children evaluated in prior studies (10,11), and no data are available specifically regarding IAs. In this prospective study, we evaluated the diagnostic role, clinical contribution, and prognostic value of fused 18 F-DOPA PET/MR images in a selected population of pediatric patients with supratentorial IAs.…”

Management of diabetes insipidus and adipsia in the child

“…MRI is the examination of choice for detecting such lesions, however in case of nonspecific MRI findings additional information can be gathered by PET imaging with amino-acid analogs such as 11C-methionine (MET) and 18F-Dihydroxyphenylalanine (DOPA). In children, the role of 18F-DOPA is well established in tumors producing an excess of catecholamine and in congenital hyperinsulinism; its diagnostic impact in the evaluation pediatric brain lesions is also emerging [40,41] (Fig. 3).…”

Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors

“…However, a clinical benefit is not infrequently lacking in patients with an impressive radiological response (pseudoresponse). [ 18 F]FET and [ 18 F]FDOPA PET may provide valuable information regarding the identification of pseudoresponse [99][100][101][102]. Moreover, [ 18 F]FDOPA and [ 18 F]FET PET were also able to predict a favorable clinical outcome in bevacizumab responders [101][102][103][104].…”